SCHEMBL874090

SCHEMBL874090

O=C(O)Cc1ncccn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.50
KDM4E B2RXH2 2/20 0.50
MAPT P10636 1/20 0.50
AKR1B1 P15121 3/20 0.44
NAPRT Q6XQN6 2/20 0.43
GABRP O00591 2/20 0.41
GABRD O14764 2/20 0.41
GABRA1 P14867 2/20 0.41
GABRB1 P18505 2/20 0.41
GABRG2 P18507 2/20 0.41
GABRB3 P28472 2/20 0.41
GABRA5 P31644 2/20 0.41
GABRA3 P34903 2/20 0.41
GABRA2 P47869 2/20 0.41
GABRB2 P47870 2/20 0.41
GABRA4 P48169 2/20 0.41
GABRE P78334 2/20 0.41
GABRA6 Q16445 2/20 0.41
GABRG1 Q8N1C3 2/20 0.41
GABRG3 Q99928 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6645397 0.97 KDM4E (0.48) CYP1A2KDM4EMAPTAKR1B1NAPRT
Furan SCHEMBL473513 0.87 CYP1A2 (0.42) CYP1A2KDM4EMAPTAKR1B1NAPRT
SCHEMBL5094342 0.81 P2RX7 (0.41) CYP1A2KDM4EMAPTNAPRTLMNA
Butyl Alcohol SCHEMBL27561770 0.81 ALDH1A1 (0.40) CYP1A2KDM4EMAPTALDH1A1HTT
SCHEMBL473621 0.77 CYP1A2 (0.35) CYP1A2KDM4EMAPTAKR1B1NAPRT
SCHEMBL7769482 0.77 P2RX7 (0.38) CYP1A2KDM4EMAPTNAPRTLMNA
SCHEMBL77616 0.77 HTT (0.48) CYP1A2KDM4EMAPTP2RX7HTT
SCHEMBL6428658 0.77 CYP1A2 (0.43) CYP1A2KDM4EMAPTAKR1B1NAPRT
SCHEMBL1719924 0.77 LMNA (0.47) CYP1A2KDM4EMAPTNAPRTLMNA
SCHEMBL8539040 0.77 P2RX7 (0.38) CYP1A2KDM4EMAPTNAPRTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 242 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117904242-B Sheep embryo extract polypeptide in Hu sheep body and application thereof in regulating immune function 蚌埠学院 2025-02-25 CN claimed
US-20070129355-A1 G-protein-coupled chemoattractant receptor, expressed on T helper cells antagonists such as [4-(dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)-5-pyrimidinyl]acetic acid;, used for the treatment of allergic diseases, inflammatory diseases, eosinophil- and basophil-related diseases ACTIMIS PHARMACEUTICALS, INC. (US) 2007-06-07 US claimed
WO-2006100552-A1 PROCESSES FOR THE PREPARATION OF LOPINAVIR AND ITS INTERMEDIATE - (S)-TETRAHYDRO-ALPHA-(1-METHYLETHYL)-2-OXO-1(2H)-PYRIMIDINEACETIC ACID RANBAXY LABORATORIES LIMITED (IN) 2006-09-28 WO claimed
EP-1471057-B1 Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2 ACTIMIS PHARMACEUTICALS INC (US) 2006-01-18 EP claimed
EP-1471057-A1 Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2 Bayer HealthCare AG (DE) 2004-10-27 EP claimed
CN-1407985-A Heterocyclic dihydropyrimidines as potassium channel inhibitors BRISTOL MYERS SQUIBB CO (US) 2003-04-02 CN claimed
US-5238907-A Substituted 2-pyrimidinyl-acetic acid derivatives, and their use as herbicides, fungicides and plant growth regulators SCHERING AKTIENGESELLSCHAFT (DE) 1993-08-24 US claimed
EP-4029868-B1 MCL-1 INHIBITORS GILEAD SCIENCES INC (US) 2026-05-20 EP disclosed
US-12565498-B2 β-lactamase inhibitors and their preparation NINGXIA ACADEMY OF AGRICULTURE AND FORESTRY SCIENCES (CN) 2026-03-03 US disclosed
CN-120137642-A Composite material, preparation method of film, photoelectric device and display equipment 广东聚华新型显示研究院 2025-06-13 CN disclosed
US-20250188032-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND USES THEREOF BNH RESEARCH CO., LTD. (KR) 2025-06-12 US disclosed
WO-2025072539-A1 AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF PLIANT THERAPEUTICS, INC. (US) 2025-04-03 WO disclosed
EP-4501910-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND USES THEREOF BNH Research Co., Ltd. (KR) 2025-02-05 EP disclosed
WO-1994022854-A1 HERBICIDAL 1,4-DI-HETEROARYL PYRAZOLIDIN-3,5-DIONES SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) 1994-10-13 WO disclosed
US-5238907-A Substituted 2-pyrimidinyl-acetic acid derivatives, and their use as herbicides, fungicides and plant growth regulators SCHERING AKTIENGESELLSCHAFT (DE) 1993-08-24 US disclosed
US-5006433-A Printing plate precursors for electrophotographic plate-making purposes FUJI PHOTO FILM CO., LTD. (JP) 1991-04-09 US disclosed
EP-0048954-B1 BETA-LACTAM COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF AND INTERMEDIATE PRODUCTS FOR THE PREPARATION THEREOF SAGAMI CHEMICAL RESEARCH CENTER (JP) 1986-12-30 EP disclosed
EP-0048954-A2 Beta-lactam compounds, process for the preparation thereof and intermediate products for the preparation thereof SAGAMI CHEMICAL RESEARCH CENTER (JP) 1982-04-07 EP disclosed
US-3929789-A Pyrimidinyl acetic acid derivatives and processes for their production ICI LTD 1975-12-30 US disclosed
US-3929789-A Pyrimidinyl acetic acid derivatives and processes for their production ICI LTD 1975-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129355-A1 G-protein-coupled chemoattractant receptor, expressed on T helper cells antagonists such as [4-(dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)-5-pyrimidinyl]acetic acid;, used for the treatment of allergic diseases, inflammatory diseases, eosinophil- and basophil-related diseases HRH2, HRH1, HRH4 CYP1A2 2709/4885KDM4E 4588/4885MAPT 2008/4885
US-12565498-B2 β-lactamase inhibitors and their preparation PGLS, MGAM, OSTC CYP1A2 1896/4885KDM4E 2288/4885MAPT 4709/4885
US-20250188032-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND USES THEREOF NLN, GRIN1, GRIN2A CYP1A2 3411/4885KDM4E 938/4885MAPT 64/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.